Peer review reports
From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
Original Submission |
17 Sep 2021 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
27 Dec 2021 |
Reviewed |
Reviewer Report
|
8 Jan 2022 |
Reviewed |
Reviewer Report
|
9 Feb 2022 |
Author responded |
Author comments - Benjamin Chastek
|
Resubmission - Version 5 |
9 Feb 2022 |
Submitted |
Manuscript version 5
|
28 Feb 2022 |
Author responded |
Author comments - Benjamin Chastek
|
Resubmission - Version 6 |
28 Feb 2022 |
Submitted |
Manuscript version 6
|
8 Mar 2022 |
Reviewed |
Reviewer Report
|
Resubmission - Version 7 |
|
Submitted |
Manuscript version 7
|
Publishing |
8 Mar 2022 |
Editorially accepted |
|
9 Apr 2022 |
Article published |
10.1186/s12876-022-02215-y
|
Learn about peer review